ReviewMolecular genetics & genomic medicine2026
Fetal Compound Heterozygous Microdeletion at 7q31.1 Involving IMMP2L: Case Report and Literature Review.
Review in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCopy number variations (CNVs) represent a significant genetic etiology for birth defects. Reports on microdeletions involving the 7q31.1 region remain scarce in the literature, with existing studies primarily documenting heterozygous deletions. Compound heterozygous chromosomal deletions inherited from non-consanguineous parents are exceptionally rare in clinical diagnostics, rendering prenatal diagnosis and genetic counseling for compound heterozygous 7q31.1 microdeletions particularly challenging. CASE REPORT: We report the first case of a homozygous 7q31.1 microdeletion inherited from both unaffected, non-consanguineous parents. While karyotyping showed a normal chromosomal result, Copy number variation sequencing (CNV-Seq) detected a homozygous microdeletion at 7q31.1. The deletion was subsequently validated as a compound heterozygous deletion by mate-pair sequencing, and its precise breakpoints were identified through Sanger sequencing. This deletion involves exons 1, 2, and 3 of the IMMP2L gene. No abnormalities were detected on prenatal ultrasound, and no obvious abnormal phenotypes were observed during immediate postnatal examination or at the 4-month follow-up. However, the patient should currently be considered asymptomatic at this early developmental stage, and the long-term consequences of biallelic IMMP2L loss in humans remain unknown.
conclusionsThe combination of prenatal ultrasound, karyotype analysis, CNV-seq, mate-pair sequencing, and genetic counseling facilitates precise prenatal diagnosis of chromosomal microdeletions and microduplications. Our case can be helpful for managing the challenges of prenatal diagnosis and genetic counseling associated with CNV of uncertain clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.